RATIONALE: Regulator of G-protein signaling 5 (RGS5) modulates G-protein-coupled receptor signaling and is prominently expressed in arterial smooth muscle cells. Our group first reported that RGS5 is important in vascular remodeling during tumor angiogenesis. We hypothesized that RGS5 may play an important role in vessel wall remodeling and blood pressure regulation. OBJECTIVE: To demonstrate that RGS5 has a unique and nonredundant role in the pathogenesis of hypertension and to identify crucial RGS5-regulated signaling pathways. METHODS AND RESULTS: We observed that arterial RGS5 expression is downregulated with chronically elevated blood pressure after angiotensin II infusion. Using a knockout mouse model, radiotelemetry, and pharmacological inhibition, we subsequently showed that loss of RGS5 results in profound hypertension. RGS5 signaling is linked to the renin-angiotensin system and directly controls vascular resistance, vessel contractility, and remodeling. RGS5 deficiency aggravates pathophysiological features of hypertension, such as medial hypertrophy and fibrosis. Moreover, we demonstrate that protein kinase C, mitogen-activated protein kinase/extracellular signal-regulated kinase, and Rho kinase signaling pathways are major effectors of RGS5-mediated hypertension. CONCLUSIONS: Loss of RGS5 results in hypertension. Loss of RGS5 signaling also correlates with hyper-responsiveness to vasoconstrictors and vascular stiffening. This establishes a significant, distinct, and causal role of RGS5 in vascular homeostasis. RGS5 modulates signaling through the angiotensin II receptor 1 and major Gαq-coupled downstream pathways, including Rho kinase. So far, activation of RhoA/Rho kinase has not been associated with RGS molecules. Thus, RGS5 is a crucial regulator of blood pressure homeostasis with significant clinical implications for vascular pathologies, such as hypertension.
RATIONALE: Regulator of G-protein signaling 5 (RGS5) modulates G-protein-coupled receptor signaling and is prominently expressed in arterial smooth muscle cells. Our group first reported that RGS5 is important in vascular remodeling during tumor angiogenesis. We hypothesized that RGS5 may play an important role in vessel wall remodeling and blood pressure regulation. OBJECTIVE: To demonstrate that RGS5 has a unique and nonredundant role in the pathogenesis of hypertension and to identify crucial RGS5-regulated signaling pathways. METHODS AND RESULTS: We observed that arterial RGS5 expression is downregulated with chronically elevated blood pressure after angiotensin II infusion. Using a knockout mouse model, radiotelemetry, and pharmacological inhibition, we subsequently showed that loss of RGS5 results in profound hypertension. RGS5 signaling is linked to the renin-angiotensin system and directly controls vascular resistance, vessel contractility, and remodeling. RGS5 deficiency aggravates pathophysiological features of hypertension, such as medial hypertrophy and fibrosis. Moreover, we demonstrate that protein kinase C, mitogen-activated protein kinase/extracellular signal-regulated kinase, and Rho kinase signaling pathways are major effectors of RGS5-mediated hypertension. CONCLUSIONS: Loss of RGS5 results in hypertension. Loss of RGS5 signaling also correlates with hyper-responsiveness to vasoconstrictors and vascular stiffening. This establishes a significant, distinct, and causal role of RGS5 in vascular homeostasis. RGS5 modulates signaling through the angiotensin II receptor 1 and major Gαq-coupled downstream pathways, including Rho kinase. So far, activation of RhoA/Rho kinase has not been associated with RGS molecules. Thus, RGS5 is a crucial regulator of blood pressure homeostasis with significant clinical implications for vascular pathologies, such as hypertension.
Authors: Christa F Gaskill; Erica J Carrier; Jonathan A Kropski; Nathaniel C Bloodworth; Swapna Menon; Robert F Foronjy; M Mark Taketo; Charles C Hong; Eric D Austin; James D West; Anna L Means; James E Loyd; W David Merryman; Anna R Hemnes; Stijn De Langhe; Timothy S Blackwell; Dwight J Klemm; Susan M Majka Journal: J Clin Invest Date: 2017-05-02 Impact factor: 14.808
Authors: T Michael De Silva; Pimonrat Ketsawatsomkron; Christopher Pelham; Curt D Sigmund; Frank M Faraci Journal: Hypertension Date: 2014-11-10 Impact factor: 10.190
Authors: Katherine E Squires; Carolina Montañez-Miranda; Rushika R Pandya; Matthew P Torres; John R Hepler Journal: Pharmacol Rev Date: 2018-07 Impact factor: 25.468
Authors: Dalya M Lateef; Cuiying Xiao; Robert J Brychta; André Diedrich; Jurgen Schnermann; Marc L Reitman Journal: Am J Physiol Heart Circ Physiol Date: 2016-01-22 Impact factor: 4.733
Authors: Maria Jelinic; Chen-Huei Leo; Emiel D Post Uiterweer; Shaun L Sandow; Jonathan H Gooi; Mary E Wlodek; Kirk P Conrad; Helena Parkington; Marianne Tare; Laura J Parry Journal: FASEB J Date: 2013-09-13 Impact factor: 5.191
Authors: Dandan Cao; Rachel W S Chan; Ernest H Y Ng; Kristina Gemzell-Danielsson; William S B Yeung Journal: Stem Cell Res Ther Date: 2021-05-29 Impact factor: 6.832